Semaglutide vs AOD 9604: Research Comparison

Research use only. This compound is sold strictly for laboratory and in-vitro research. It is not a drug, supplement, food, or cosmetic, is not approved by the FDA, is not intended to diagnose, treat, cure, or prevent any disease, and is not for human or animal consumption. Dosing figures are reference values from the research literature for laboratory models only.

Semaglutide vs AOD 9604 at a glance

	Semaglutide	AOD 9604
Also known as	GLP-1 agonist	HGH Fragment 176-191
Category	Fat Loss & Weight Management	Fat Loss & Weight Management
Format	SubQ	SubQ
Research level	Beginner	Beginner
Research sizes	2 mg vial, 5 mg vial, 10 mg vial	5 mg vial, 10 mg vial
In one line	A long-acting GLP-1 receptor agonist studied extensively in metabolic research.	A growth-hormone fragment studied for lipolysis research without blood-sugar effects.

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a long half-life. It is among the most-studied metabolic research peptides because of the extensive GLP-1 literature on glucose handling and satiety signaling.

Semaglutide research centers on GLP-1-receptor activation: enhanced glucose-dependent insulin signaling, slowed gastric emptying, and central satiety pathways. These endpoints are studied in metabolic and weight-related research models.

What is AOD 9604?

AOD 9604 is a modified fragment (residues 176-191) of human growth hormone, representing the region associated with fat metabolism. It is studied because it isolates the lipolytic portion of GH without the growth-signaling or glucose effects of the whole hormone.

AOD 9604 research focuses on stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis without acting on the IGF-1 axis or blood glucose - the defining research feature.

Key research differences

The two are best understood by what each is studied for. Semaglutide: Semaglutide is a single-pathway GLP-1 agonist; Tirzepatide is a dual GLP-1/GIP agonist. The two are the central comparison in modern metabolic-peptide research. AOD 9604: Unlike GLP-1 peptides that act on appetite, AOD 9604 isolates the fat-metabolism portion of GH and does not affect blood sugar - a distinct research mechanism.

How researchers choose between them

Because Semaglutide and AOD 9604 both sit in the fat loss & weight management category, the choice is a research-design question: match the compound to the exact signal or endpoint your model targets, and in many protocols the two are studied in parallel or in sequence rather than as either/or. Whichever you select, compare on verified quality: both are third-party tested to a 99%+ purity target with a COA on request.

Order Semaglutide or AOD 9604

Both available research-grade with a COA on request.

See pricing & sizes

Frequently asked questions

What is the difference between Semaglutide and AOD 9604?

Semaglutide a long-acting GLP-1 receptor agonist studied extensively in metabolic research; AOD 9604 a growth-hormone fragment studied for lipolysis research without blood-sugar effects. Both are fat loss & weight management research peptides. Both are research-use-only.

Can Semaglutide and AOD 9604 be studied together?

Yes - within the same category they are often studied in parallel or sequence to compare or combine effects. Any combination work is laboratory research only.

Which is better, Semaglutide or AOD 9604?

Neither is universally "better" - the right choice depends on the research question. Match the compound to your model's target signal, and compare suppliers on verifiable third-party purity, not sticker price.

All comparisons · Semaglutide · AOD 9604 · Semaglutide cost

External references: Peptide (Wikipedia) · U.S. Food and Drug Administration

Both compounds are sold for laboratory and research use only and are not for human or animal consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.